JP2022512824A5 - - Google Patents

Info

Publication number
JP2022512824A5
JP2022512824A5 JP2021522993A JP2021522993A JP2022512824A5 JP 2022512824 A5 JP2022512824 A5 JP 2022512824A5 JP 2021522993 A JP2021522993 A JP 2021522993A JP 2021522993 A JP2021522993 A JP 2021522993A JP 2022512824 A5 JP2022512824 A5 JP 2022512824A5
Authority
JP
Japan
Prior art keywords
crystalline compound
composition
compound according
approximately
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522993A
Other languages
English (en)
Japanese (ja)
Other versions
JP7504880B2 (ja
JP2022512824A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058062 external-priority patent/WO2020086963A1/en
Publication of JP2022512824A publication Critical patent/JP2022512824A/ja
Publication of JP2022512824A5 publication Critical patent/JP2022512824A5/ja
Priority to JP2024094803A priority Critical patent/JP2024107352A/ja
Application granted granted Critical
Publication of JP7504880B2 publication Critical patent/JP7504880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522993A 2018-10-26 2019-10-25 Alk2阻害剤の結晶形 Active JP7504880B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094803A JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751255P 2018-10-26 2018-10-26
US62/751,255 2018-10-26
PCT/US2019/058062 WO2020086963A1 (en) 2018-10-26 2019-10-25 Crystal forms of an alk2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094803A Division JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Publications (3)

Publication Number Publication Date
JP2022512824A JP2022512824A (ja) 2022-02-07
JP2022512824A5 true JP2022512824A5 (cg-RX-API-DMAC7.html) 2022-10-27
JP7504880B2 JP7504880B2 (ja) 2024-06-24

Family

ID=70330555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522993A Active JP7504880B2 (ja) 2018-10-26 2019-10-25 Alk2阻害剤の結晶形
JP2024094803A Pending JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094803A Pending JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Country Status (8)

Country Link
US (1) US12071438B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870181B1 (cg-RX-API-DMAC7.html)
JP (2) JP7504880B2 (cg-RX-API-DMAC7.html)
CN (1) CN114269345B (cg-RX-API-DMAC7.html)
AU (1) AU2019364631B2 (cg-RX-API-DMAC7.html)
CA (1) CA3117695A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020086963A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103228B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
EP4294403A4 (en) * 2021-02-18 2024-12-11 Beren Therapeutics P.B.C. METHODS OF TREATMENT OF HETEROZYGOUS AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20190055192A1 (en) 2004-06-07 2019-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
DE602005023763D1 (de) * 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
US7790407B2 (en) 2005-11-29 2010-09-07 Nevada Cancer Institute Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN105503882B (zh) * 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
JP6542192B2 (ja) * 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
JP7175917B2 (ja) * 2017-04-27 2022-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 新規のalk2阻害剤及びbmpシグナル伝達の阻害方法
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
MX2020005405A (es) 2017-11-24 2020-08-13 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
MX2022001741A (es) 2019-08-13 2022-03-11 Blueprint Medicines Corp Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina.
WO2021067670A1 (en) 2019-10-02 2021-04-08 Blueprint Medicines Corporation Process for preparing an activin receptor-like kinase inhibitor
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
US20250034148A1 (en) 2021-11-02 2025-01-30 Keros Therapeutics, Inc. Methods of using alk2 inhibitors

Similar Documents

Publication Publication Date Title
JP2020519654A5 (cg-RX-API-DMAC7.html)
JP2017504591A5 (cg-RX-API-DMAC7.html)
CN108289457B (zh) 抗真菌化合物制备方法
JP2022502500A5 (cg-RX-API-DMAC7.html)
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
JP2021119136A5 (cg-RX-API-DMAC7.html)
JP2013523733A5 (cg-RX-API-DMAC7.html)
JP2015520151A5 (cg-RX-API-DMAC7.html)
RU2017115925A (ru) Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
JP2012523395A5 (cg-RX-API-DMAC7.html)
JP2015503610A5 (cg-RX-API-DMAC7.html)
JP2014502641A5 (cg-RX-API-DMAC7.html)
JP7159440B2 (ja) ジカチオン化合物及びその製造方法と使用
JP2016505071A5 (cg-RX-API-DMAC7.html)
JP2010132669A (ja) ストロンチウムラネレートのアルファー(α)−結晶形、その製造方法、及びそれを含む医薬組成物
JP2022523368A5 (cg-RX-API-DMAC7.html)
JP2024541569A5 (cg-RX-API-DMAC7.html)
JP2025508071A5 (cg-RX-API-DMAC7.html)
JP7471685B2 (ja) 新規な化合物およびそれを含むがんの予防または治療用薬学組成物
JP2019516749A5 (cg-RX-API-DMAC7.html)
TWI694986B (zh) 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途
JP2013508385A5 (cg-RX-API-DMAC7.html)
JP2014508106A (ja) スフィンゴシン−1−リン酸−1受容体モジュレーターとしてのアルキンおよびアルケン誘導体
JP2018509426A5 (cg-RX-API-DMAC7.html)
RU2013125756A (ru) Твердые формы (s)-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропановой кислоты